EFZO-FIT™: A Phase 3 Study of Efzofitimod, a Novel Immunomodulator for the Treatment of Pulmonary Sarcoidosis

World Association for Sarcoidosis and Other Granulomatous Disorders, 2023

« Exposure-Efficacy Analysis Supports Proof of Concept for Efzofitimod in Pulmonary Sarcoidosis

Efzofitimod: A Novel Therapeutic Candidate for SSc-ILD »

© 2007 - 2024 aTyr Pharma. Legal Privacy Policy